JNJ: Q2 2026 delivered 6.6% sales growth and raised guidance, led by innovation and pipeline momentum
Q2 2026 saw 6.6% sales growth to $25.3B and adjusted EPS up 4.7% to $2.90, driven by innovation and strong performance in Innovative Medicine and MedTech. Full-year guidance was raised, with operational sales growth expected at 6.8% and key pipeline milestones ahead.Original document: Johnson & Joh…